Publicacións nas que colabora con José Seijas Amigo (11)
2024
-
Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study
Diseases, Vol. 12, Núm. 10
2023
-
Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials
The American journal of cardiology, Vol. 205, pp. 321-324
-
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study
American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593
-
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372
-
Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342
-
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis
Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75
2022
-
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry
European Journal of Clinical Investigation, Vol. 52, Núm. 12
-
Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252
-
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry
Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529
2020
-
Estimation of the major cardiovascular events prevention with Inclisiran
Atherosclerosis, Vol. 313, pp. 76-80
-
Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials
Journal of Diabetes and Metabolic Disorders, Vol. 19, Núm. 2, pp. 759-765